Consensus interferon versus interferon-α 2b plus ribavirin in patients with relapsing HCV infection

Hepatology Research

Volumn 27, Issue 4, 2003, Pages 253-259

  Miglioresi, Lucia ^a   Bacosi, Marco ^a   Russo, Francesca ^a   Patrizi, Franca ^b   Saccenti, Patrizia ^b   Ursitti, Antonella ^c   De Angelis, Anna ^c   Ricci, Giovanni L ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b Associazione Romana Ricerche Clin   (Italy)

^c SANDRO PERTINI HOSPITAL   (Italy)

Author keywords

Consensus interferon; Hepatitis C; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; CONSENSUS INTERFERON; FLUNITRAZEPAM; LORAZEPAM; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS RNA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; BIOCHEMISTRY; CLEARANCE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HEMOGLOBINURIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THYROID DISEASE; TREATMENT OUTCOME;

EID: 0346895109     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(03)00269-9     Document Type: Article

References (25)

1. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;19(339):1485-92.
2. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
3. Bacosi M, Patsouri M, Miglioresi L, Patrizi F, Russo F, Ricci GL. Combined treatment of HCV infection: is there a need for meta-analysis? Hepatol Res 2001;20:359-71.
4. Zeuzem S. What is (cost) effective in patients with chronic hepatitis C virus infection? Eur J Gastroenterol Hepatol 2001;13:473-6.
5. Fontana RJ, Walsh J, Moyer CA, Lok AS, Webster S, Klein S. High-dose interferon alpha-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomised, controlled trial. J Clin Gastroenterol 2002;34:177-82.
6. Bonkovsky HL, Stefancyk D, McNeal K, Banner BF, Liu Q, Zucker GM, et al. Comparative effects of different doses of ribavirin plus interferon alpha-2b for therapy of chronic hepatitis C: results of a controlled, randomised trial. Dig Dis Sci 2001;46:2051-9.
7. Cozzolongo R, Cuppone R, Giannuzzi V, Amati L, Caradonna L, Tamborrino V, et al. Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. Aliment Pharmacol Ther 2001;15:129-35.
8. Marco VD, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo MG, et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha-2b interferon plus ribavirin for 6 or 12 months. J Hepatol 2000;33:456-62.
9. Ozes ON, Reiter ZVI, Klein S, et al. A comparison of interferon alphacon-1 with natural recombinant interferons-α: anti-viral, anti-proliferative and natural killer-inducing activities. J Interferon Res 1992;12:55-9.
10. Neumann AU, Rajender Reddy K, Levi-Drummer R, et al. Hepatitis C viral dynamics in vivo and the anti-viral efficacy of interferon alpha therapy. Science 1998;282:103-7.
11. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keefe EB, et al. Treatment of chronic hepatitis C with consensus interferon: a multi-centre, randomised, controlled trial. Consensus Interferon Study Group. Hepatology 1997;26:747-54.
12. Heathcote EJ, Keefe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
13. Russo F, Bacosi M, Marinelli RMA, Miglioresi L, Ricci GL. Leucopenia is a side effect of combination therapy for hepatitis C infection. Am J Gastroent 2000;95:1100.
14. Ishak K, Baptisa A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
15. Hoefs JC, Wang F, Kanel G, Braunstein P. The liver-spleen scan as a quantitative liver function test: correlation with liver severity at peritoneoscopy. Hepatology 1995;22:1113-21.
16. Salerno G, Delle Monache M, Ronga G, Gerardi R, Berardo C, Ricci GL. Hepatic 99mTc-phytate scintigraphy in cirrhosis: a reliable or outdated test. MEDIC 1994;2:251-5.
17. Sullivan DC. The use of ultrasound to enhance the diagnostic utility of the equivocal liver scintigraphy. Radiology 1978;128:727-31.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peg-interferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
19. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peg-interferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
20. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V, et al. Re-treatment for 24 versus 48 weeks with interferon-alpha-2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000;7:403-8.
21. Cavalletto L, Chemello L, Donada C, Casarin P, Belussi F, Bernardinello E, et al. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin re-treatment for chronic hepatitis C. TVVH Study Group. J Hepatol 2000;33:128-34.
22. Kao JH, Chen PJ, Lai MY, Chen DS. Efficacy of consensus interferon in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2000;15:1418-23.
23. Yao GB, Fu XX, Tian GS, et al. A multi-centre, randomised, controlled trial of interferon alphacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2000;15:1165-70.
24. Kaiser S, Kreysel C, Hass H, Gregor M. High viral response rates in previous non-responder patients with hepatitis C treated with daily dosing of consensus interferon and ribavirin. J Hepatol 2002;36(Suppl 1):18A.
25. Kaiser S, Kreysel C, Hass H, Gregor M. High dose induction therapy with consensus interferon and ribavirin for treatment of naïve patients with hepatitis C. J Hepatol 2002;36(Suppl 1):113A.